Form 4: Marinus Pharmaceuticals Director Timothy Mayleben Reports Disposal of Shares and Stock Options Following Merger Agreement

Director Timothy Mayleben reports the disposal of common stock and stock options due to the merger agreement with Immedica Pharma AB, where shares were acquired at $0.55 per share.

Summary

• Timothy Mayleben, a director of Marinus Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• The filing is related to the merger agreement between Marinus Pharmaceuticals and Immedica Pharma AB, where Immedica's subsidiary acquired Marinus's common stock at $0.55 per share.
• Mayleben disposed of 4,600 shares of common stock directly and 14,957 shares indirectly through various trusts at $0.55 per share on February 7, 2025.
• Additionally, 2,300 Restricted Stock Units (RSUs) were terminated, resulting in a cash payment based on the offer price.
• Out-of-the-money stock options were terminated without any payment to Mayleben.
• The transactions occurred on February 7 and February 11, 2025.
• The reporting person is the sole trustee of the Timothy M. Mayleben Revocable Trust U/A/D 9/16/16.
• The reporting person disclaims beneficial ownership of shares held in the Ellery A. Mayleben 2017 Trust and the Kasey D. Evans 2017 Trust.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it primarily reports the execution of a pre-existing merger agreement. There are no indications of unexpected positive or negative outcomes.

Future Outlook

The document does not contain specific forward-looking statements beyond the completion of the merger.

Industry Context

This announcement reflects a merger and acquisition activity within the pharmaceutical industry, where companies are often acquired for their assets, technologies, or market positions.

Comparison to Industry Standards

• Comparing this acquisition to similar deals in the pharmaceutical sector, the valuation of $0.55 per share would be assessed against precedent transactions involving companies with similar pipelines and market capitalization.
• Comparable companies might include those acquired by larger pharmaceutical firms for their specific drug candidates or technologies.
• The termination of out-of-the-money stock options is a standard practice in M&A transactions.

Stakeholder Impact

• Shareholders received $0.55 per share as part of the merger agreement.
• Employees may experience changes as a result of the merger.

Key Dates

Keywords

Form 4, Marinus Pharmaceuticals, Timothy Mayleben, Immedica Pharma AB, Merger Agreement, Beneficial Ownership, Stock Options, Common Stock, RSUs, Director